var data={"title":"Dofetilide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dofetilide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6065?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dofetilide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dofetilide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708707\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Arrhythmias:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">To minimize the risk of induced arrhythmia, patients initiated or re-initiated on dofetilide should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162348\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tikosyn</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162368\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiarrhythmic Agent, Class III</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162351\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> CrCl and QTc (or QT interval if heart rate is &lt;60 beats/minute) must be determined prior to first dose. If QTc &gt;440 msec (&gt;500 msec in patients with ventricular conduction abnormalities), dofetilide is contraindicated. <b>Adjust initial dosage in patients with estimated CrCl &lt;60 mL/minute (see dosage adjustment in renal impairment).</b> Dofetilide may be initiated at lower doses than recommended based on physician discretion; however, if the lower dose is increased, the patient will require rehospitalization for 3 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation/atrial flutter:</b> Oral: Initial: 500 mcg twice daily (maximum dose: 500 mcg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Supraventricular tachycardia (ongoing management) (off-label use): </b>Oral: Initial: 500 mcg every 12 hours (ACC/AHA/HRS [Page 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Modification of dosage in response to <b>initial</b> dose:</i> QTc interval should be measured 2 to 3 hours after the initial dose. If the QTc increases to more than 15% above baseline QTc or if the QTc is &gt;500 msec (&gt;550 msec in patients with ventricular conduction abnormalities), dofetilide dose should be reduced by 50%. If the starting dose was 500 mcg twice daily, then reduce to 250 mcg twice daily. If the starting dose was 250 mcg twice daily, then reduce to 125 mcg twice daily. If the starting dose was 125 mcg twice daily, then reduce to 125 mcg once daily. QTc interval should be measured 2 to 3 hours after each subsequent dose (in-hospital doses 2 through 5). If at any time after the second dose the QTc is &gt;500 msec (&gt;550 msec in patients with ventricular conduction abnormalities), dofetilide should be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Maintenance therapy:</i> No further down titration of dose based on QTc is recommended following modification of initial dose. Renal function and QTc should be re-evaluated every 3 months or as medically warranted. If QTc &gt;500 msec (&gt;550 msec in patients with ventricular conduction abnormalities), discontinue therapy. If renal function deteriorates, adjust dose as described in dosage adjustment in renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162352\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. No specific dosage adjustments are recommended based on age; however, careful assessment of renal function is particularly important in this population.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162353\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Using the Modification of Diet in Renal Disease (MDRD) equation and subsequent eGFR to determine dose may lead to overestimation of CrCl and overdose of medication; use only the Cockcroft-Gault equation to estimate CrCl (Denetclaw 2011). Use actual body weight when using the Cockcroft-Gault equation to calculate CrCl (weight range of patients enrolled in clinical trials: 40 to 134 kg).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &gt;60 mL/minute: Initial: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 40 to 60 mL/minute: Initial: 250 mcg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 20 to 39 mL/minute: Initial: 125 mcg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;20 mL/minute: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162354\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild or moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hepatic impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162327\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tikosyn: 125 mcg, 250 mcg, 500 mcg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mcg, 250 mcg, 500 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162313\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13160861\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM266314.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68//lap83WwXcI2p08TWQaqw==&amp;TOPIC_ID=8904\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM266314.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46324303\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with or without food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162328\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Atrial fibrillation/atrial flutter:</b> Maintenance of normal sinus rhythm in patients with chronic atrial fibrillation/atrial flutter of longer than 1-week duration who have been converted to normal sinus rhythm; conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725332\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Atrial fibrillation in patients with hypertrophic cardiomyopathy; Supraventricular tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13934279\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dofetilide may be confused with defibrotide </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162320\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Torsades de pointes (patients receiving doses in excess of those recommended: &le;11%; cardiac failure patients: 3%; patients with recent myocardial infarction: &lt;1%; occurs most frequently within the first 3 days of therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (10%), ventricular fibrillation (&le;5%), ventricular tachycardia (3% to 4%), bradycardia (&le;2%), cardiac arrest (&le;2%), cerebral ischemia (&le;2%), cerebrovascular accident (&le;2%), edema (&le;2%), myocardial infarction (&le;2%), syncope (&le;2%), atrioventricular block (&lt;2%), heart block (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (8%), insomnia (4%), facial paralysis (&le;2%), flaccid paralysis (&le;2%), migraine (&le;2%), paralysis (&le;2%), paresthesia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (5%), abdominal pain (3%), diarrhea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatotoxicity (&le;2%), hepatic injury (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Angioedema (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Respiratory tract infection (7%), dyspnea (6%), flu-like symptoms (4%), increased cough (&le;2%), cough (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (3%), surgery (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Bundle branch block</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162332\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to dofetilide or any component of the formulation; congenital or acquired long QT syndromes; patients with baseline QT interval or QTc &gt;440 msec (500 msec in patients with ventricular conduction abnormalities); severe renal impairment (CrCl &lt;20 mL/minute); concurrent use with cimetidine, dolutegravir, hydrochlorothiazide (alone or in combinations), itraconazole (according to itraconazole prescribing information), ketoconazole, megestrol, prochlorperazine, trimethoprim (alone or in combination), or verapamil</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162317\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Proarrhythmic effects: May cause serious ventricular arrhythmias, primarily torsades de pointes (TdP). Watch for proarrhythmic effects; monitor and adjust dose to prevent QTc prolongation; reduced CrCl or certain dofetilide drug interactions will increase dofetilide plasma concentration. Risk of TdP significantly increases with doses greater than the maximum dose of 500 mcg twice daily. The risk of TdP may be higher in certain patient subgroups (eg, patients with heart failure). Most episodes of TdP occur within the first 3 days of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias: Appropriate use: Reserve for patients who are highly symptomatic with atrial fibrillation/atrial flutter. <b>[US Boxed Warning]:  Must be initiated (or reinitiated) in a setting that can provide continuous monitoring of CrCl and ECG monitoring and cardiac resuscitation with staff familiar with the recognition and treatment of life-threatening arrhythmias for a minimum of 3 days,</b> or for a minimum of 12 hours after electrical or pharmacological cardioversion to normal sinus rhythm, whichever is greater. Patients should be readmitted for continuous monitoring if dosage is later increased.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conduction disturbances: Use with caution in patients with second or third-degree heart block and/or sick sinus syndrome unless a functional pacemaker is in place; these patients were not included in phase 3 clinical trials. However, no effect on AV nodal conduction seen in patients with normal conduction and those with first-degree heart block. Defibrillation threshold is reduced in patients with ventricular tachycardia or ventricular fibrillation undergoing implantation of a cardioverter-defibrillator device.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; systemic clearance of dofetilide is decreased and plasma concentration increased with decreasing CrCl. <b>Dose adjustment is required for patients with CrCl &le;60 mL/minute.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162363\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162322\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8904&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AMILoride: May increase the serum concentration of Dofetilide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Dofetilide.<b> Exceptions: </b>Fluconazole; Isavuconazonium Sulfate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: May increase the serum concentration of Dofetilide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Dofetilide. This is likely via inhibition of dofetilide renal tubular secretion (primarily) and inhibition of dofetilide metabolism.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Dofetilide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Dofetilide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dofetilide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Weak): May increase the serum concentration of Dofetilide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: May increase the serum concentration of Dofetilide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May increase the serum concentration of Dofetilide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the QTc-prolonging effect of Dofetilide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Megestrol: May increase the serum concentration of Dofetilide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: May increase the serum concentration of Dofetilide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prochlorperazine: May increase the serum concentration of Dofetilide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May enhance the arrhythmogenic effect of Dofetilide. Saquinavir may increase the serum concentration of Dofetilide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the QTc-prolonging effect of Dofetilide. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Dofetilide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Triamterene: May increase the serum concentration of Dofetilide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of Dofetilide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: May increase the serum concentration of Dofetilide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162323\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162335\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20306042\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if dofetilide is excreted in breast milk. Breast-feeding is not recommended by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162325\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG monitoring with attention to QT (if heart rate &lt;60 beats per minute) or QTc and occurrence of ventricular arrhythmias, baseline serum creatinine and changes in serum creatinine. Upon initiation (or reinitiation) continuous ECG monitoring recommended for a minimum of 3 days, or for at least 12 hours after electrical or pharmacological conversion to normal sinus rhythm, whichever is greater. Monitor serum potassium and magnesium levels at baseline and throughout therapy. QT or QTc must be monitored at baseline prior to the first dose and 2 to 3 hours afterwards. If at baseline, QTc &gt;440 msec (&gt;500 msec in patients with ventricular conduction abnormalities), use is contraindicated. If dofetilide initiated, QTc interval must be determined 2 to 3 hours after each subsequent dose of dofetilide for in-hospital doses 2 to 5. Thereafter, QT or QTc and CrCl should be evaluated every 3 months. If at any time during therapy after the second dose the measured QTc is &gt;500 msec (&gt;550 msec in patients with ventricular conduction abnormalities), dofetilide should be discontinued.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\"> Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162316\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Vaughan Williams Class III antiarrhythmic activity. Blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current. Dofetilide has no effect on sodium channels, adrenergic alpha-receptors, or adrenergic beta-receptors. It increases the monophasic action potential duration due to delayed repolarization. The increase in the QT interval is a function of prolongation of both effective and functional refractory periods in the His-Purkinje system and the ventricles. Changes in cardiac conduction velocity and sinus node function have not been observed in patients with or without structural heart disease. PR and QRS width remain the same in patients with preexisting heart block and or sick sinus syndrome.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162331\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 3 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 60% to 70% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4 (low affinity); metabolites formed by N-dealkylation and N-oxidation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: &gt;90% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~10 hours; prolonged with renal impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Fasting: 2 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (80%; ~80% as unchanged drug, 20% as inactive or minimally active metabolites); renal elimination consists of glomerular filtration and active tubular secretion via cationic transport system</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162334\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Dofetilide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (60): $513.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (60): $513.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg (60): $513.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tikosyn Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (40): $498.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (40): $498.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg (40): $498.86</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Choy AM, Darbar D, Dell'Orto S, et al, &ldquo;Exaggerated QT Prolongation After Cardioversion of Arterial Fibrillation,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 34(2):396-401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dofetilide-drug-information/abstract-text/10440151/pubmed\" target=\"_blank\" id=\"10440151\">10440151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Denetclaw TH, Oshima N, and Dowling TC, &ldquo;Dofetilide Dose Calculation Errors in Elderly Associated With Use of the Modification of Diet in Renal Disease Equation,&rdquo; <i>Ann Pharmacother</i>, 2011, 45(7-8):e44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dofetilide-drug-information/abstract-text/21712508/pubmed\" target=\"_blank\" id=\"21712508\">21712508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(24):e783-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dofetilide-drug-information/abstract-text/22068434/pubmed\" target=\"_blank\" id=\"22068434\">22068434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dofetilide-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&oslash;ber L, Bloch Thomsen PE, M&oslash;ller M, et al, &quot;Effect of Dofetilide in Patients With Recent Myocardial Infarction and Left-Ventricular Dysfunction: A Randomised Trial,&quot; <i>Lancet</i>, 2000, 356(9247):2052-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dofetilide-drug-information/abstract-text/11145491/pubmed\" target=\"_blank\" id=\"11145491\">11145491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mounsey JP and DiMarco JP, &ldquo;Dofetilide,&rdquo; <i>Circulation</i>, 2000, 102(21):2665-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dofetilide-drug-information/abstract-text/11085972/pubmed\" target=\"_blank\" id=\"11085972\">11085972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naccarelli GV, Wolbrette DL, Khan M, et al, &ldquo;Old and New Antiarrhythmic Drugs for Converting and Maintaining Sinus Rhythm in Atrial Fibrillation: Comparative Efficacy and Results of Trials,&rdquo; <i>Am J Cardiol</i>, 2003, 91(6A):15D-26D.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dofetilide-drug-information/abstract-text/12670638/pubmed\" target=\"_blank\" id=\"12670638\">12670638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dofetilide-drug-information/abstract-text/26409259/pubmed\" target=\"_blank\" id=\"26409259\">26409259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh S, Zoble RG, Yellen L, et al, &ldquo;Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter,&rdquo; <i>Circulation</i>, 2000, 102(19):2385-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dofetilide-drug-information/abstract-text/11067793/pubmed\" target=\"_blank\" id=\"11067793\">11067793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tikosyn (dofetilide) [prescribing information]. New York, NY: Pfizer; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torp-Pederson C, Moller M, Bloch-Thomsen PE, et al, &ldquo;Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction,&rdquo; <i>N Engl J Med</i>, 1999, 341(12):857-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dofetilide-drug-information/abstract-text/10486417/pubmed\" target=\"_blank\" id=\"10486417\">10486417</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8904 Version 135.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708707\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F162348\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F162368\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F162351\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F162352\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F162353\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F162354\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F162327\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F162313\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F13160861\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46324303\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F162328\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725332\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13934279\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F162320\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F162332\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F162317\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F162363\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F162322\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F162323\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F162335\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20306042\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F162325\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F162316\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F162331\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F162334\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8904|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dofetilide-patient-drug-information\" class=\"drug drug_patient\">Dofetilide: Patient drug information</a></li></ul></div></div>","javascript":null}